Good morning, everyone, and welcome, everyone, to the Prelude Therapeutics Investor Conference Call. Today's call is being recorded and is expected to last up to 45 minutes. At this time, I will now ...
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the 15 stocks set to explode in 2026. On November 7, 2025, Summit ...
This trial represents the first major advancement in second-line GIST treatment in over two decades, potentially transforming the therapeutic landscape. Cogent Biosciences announced positive results ...
A flu strain that emerged over the summer is causing "unprecedented" outbreaks in Japan, as well as in Canada and the U.K.
Scientists using TwinsUK data and ultra‑precise DNA sequencing have uncovered rare DNA mutations in healthy tissue that could ...
Effective management of inherited retinal diseases requires a comprehensive approach to diagnosis and treatment, according to ...
Experts warn the UK could see its worst flu season in a decade after the virus appears to have changed 'more than expected' ...
Discusses Positive Phase 3 PEAK Trial Results of Bezuclastinib in Gastrointestinal Stromal Tumors November 8:00 ...
New research using data from the TwinsUK cohort has helped reveal how naturally occurring DNA mutations in healthy tissue may contribute to ageing and ...
Vesper Bio announces positive Phase Ib/IIa topline results for lead candidate VES001 for frontotemporal degeneration Phase Ib/IIa study found VES001, the first oral therapy being tested in FTD, led to ...
Cassava Sciences, Inc. (NASDAQ: SAVA, "Cassava", the "Company"), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback